Beyond Air, Inc. (NASDAQ:XAIR – Get Free Report) CEO Robert Scott Goodman purchased 34,722 shares of the business’s stock in a transaction on Wednesday, July 29th. The stock was acquired at an average price of $5.76 per share, with a total value of $199,998.72. Following the completion of the acquisition, the chief executive officer directly owned 34,822 shares in the company, valued at $200,574.72. The trade was a 34,722.00% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.
Beyond Air Trading Down 2.6%
NASDAQ XAIR traded down $0.14 during trading hours on Friday, hitting $5.28. 27,954 shares of the company’s stock were exchanged, compared to its average volume of 168,749. The business’s 50 day moving average is $7.75 and its 200-day moving average is $14.27. Beyond Air, Inc. has a 12-month low of $5.02 and a 12-month high of $95.60. The firm has a market capitalization of $3.81 million, a P/E ratio of -0.06 and a beta of 0.22. The company has a debt-to-equity ratio of 3.48, a quick ratio of 3.59 and a current ratio of 3.80.
Beyond Air (NASDAQ:XAIR – Get Free Report) last posted its quarterly earnings results on Friday, June 26th. The company reported ($15.40) EPS for the quarter, missing the consensus estimate of ($11.33) by ($4.07). Beyond Air had a negative net margin of 432.99% and a negative return on equity of 350.00%. The business had revenue of $1.91 million during the quarter, compared to analysts’ expectations of $2.30 million.
Institutional Trading of Beyond Air
Analyst Upgrades and Downgrades
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Beyond Air in a report on Tuesday, July 21st. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Beyond Air has an average rating of “Hold” and an average target price of $200.00.
Read Our Latest Stock Report on XAIR
Beyond Air Company Profile
Beyond Air, Inc is a clinical-stage medical technology company focused on the development and commercialization of inhaled nitric oxide (NO) therapy for pulmonary and respiratory diseases. The company’s proprietary LungFit® platform delivers pulsed, low-dose nitric oxide gas through compact, portable devices designed to support treatments in both inpatient and outpatient settings. Beyond Air’s approach leverages NO’s antimicrobial, vasodilatory and anti-inflammatory properties to address a range of unmet needs in respiratory medicine.
The company’s lead candidate, LungFit® PH, is under investigation for the treatment of pulmonary hypertension, with ongoing clinical studies assessing its impact on pulmonary arterial pressure and exercise capacity.
Further Reading
- Five stocks we like better than Beyond Air
- Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
- Apple’s Record Quarter Could Not Outrun Its Guidance Problem
- McKesson’s Compounding Keeps Adding Up
Receive News & Ratings for Beyond Air Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyond Air and related companies with MarketBeat.com's FREE daily email newsletter.
